Compare Heron Therapeutics Inc (HRTX) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Nuscale Power Corporation — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Nuscale Power Corporation trades at $7.11 (market cap $3.00B). The key difference: Nuscale Power Corporation is far larger — about 44.1× Heron Therapeutics Inc's market cap, and Heron Therapeutics Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Nuscale Power Corporation for 29 Days on average.
| HRTX | SMR | |
|---|---|---|
Market Cap | $68.01M | $3.00B |
Volume | 1,891,941 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $1.49 | $53.43 |
52-Week Low | $0.27 | $7.32 |
Typical Hold Time | 35 Days | 29 Days |
Enterprise Value | $174.75M | $1.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
SMR stock trades at $7.23, down 5.74% on the day, reflecting a bearish technical trend and weak financial performance. The company reported a net loss of $355.79 million in 2025 on revenue of $31.48 million, with a negative net income margin of -3,888.7%. Despite analyst consensus pointing to a $11.25 price target, recent news highlights an ongoing SEC investigation and intense competition in the small modular reactor market.
The outlook remains highly speculative, with significant execution risk and cash burn offsetting long-term potential in the nuclear energy sector. While institutional interest and a 50% buy rating suggest some optimism, the stock's high volatility and lack of profitability present substantial risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
